Abbott Laboratories Share Price Slides Sharply as Revenue Misses Rattle Stock Market Today

Market Performance

The Abbott Laboratories share price came under heavy pressure in the stock market today, sliding sharply as investors reacted to weaker-than-expected numbers and cautious guidance.

By late morning in New York, Abbott shares were trading at $110.94, down $9.79 or 8.11%. The stock had closed at $120.73 in the previous session. Over the last 12 months, the share price is still up 3.4%, but Thursday’s move showed how quickly sentiment can turn when expectations aren’t met.

The sharp fall reflected disappointment on two fronts—fourth-quarter revenue and the outlook for the first quarter.

Main News Driving Abbott Laboratories Share Price Lower

Abbott announced that its Q4 revenue stood at $11.5 billion, falling short of market expectations of $11.8 billion. That gap, though it may look small on paper, was enough to unsettle investors already on edge.

Adjusted earnings for the quarter came in at $1.50 per share. While profits remained solid, revenue weakness became the key concern.

The pressure didn’t stop there.

For the first quarter, Abbott projected adjusted earnings per share of $1.12 to $1.18. The lower end of this range played a big role in pushing the Abbott Laboratories share price down in the stock market today, as investors reacted to softer near-term visibility.

Company Details: Where the Numbers Tell the Story?

Abbott’s business spans multiple healthcare segments, and the latest results showed a mixed picture across divisions.

Key financial highlights from Q4:

• Total Revenue: $11.5 billion
• Adjusted EPS: $1.50
• Nutrition Revenue: $1.9 billion
• Medical Devices Revenue: $5.67 billion

The biggest drag came from the nutrition segment.

Nutrition revenue stood at $1.9 billion, well below earlier benchmarks. The company’s pediatric nutrition business has been under pressure due to:

• Loss of a major US government supply contract last year
• Rising manufacturing and production costs
• Increased competition in consumer nutrition products

Higher production costs pushed prices up, and that, in turn, affected demand as consumers became more price-sensitive.

Medical Devices and Diagnostics: Stable but Uneven

Abbott’s medical devices segment, its largest business, recorded $5.67 billion in Q4 revenue. This met expectations and offered some stability amid broader uncertainty.

This division includes products such as:

• Continuous glucose monitoring systems
• Devices used by diabetic patients for blood sugar tracking

On the diagnostics side, the picture remained softer.

Demand for testing products has declined since pandemic-era highs. Abbott acknowledged that its diagnostics business faced a $1 billion headwind last year, largely linked to falling Covid-related testing demand.

That pressure is now mostly behind the company, but the impact has already been felt in recent quarters.

Other Business Developments in Focus

Abbott continues to operate across a wide healthcare spectrum:

• Surgical tools
• Infant and adult nutrition products
• Specialized wellness supplements

Its adult nutrition segment, including protein-rich products tailored for people using weight-management medications, has shown recent growth.

At the same time, its infant formula business remains tied up in ongoing legal challenges related to claims of health risks in premature infants. These issues continue to sit in the background as part of the broader business narrative.

Abbott has also entered into an agreement to acquire Exact Sciences Corp., with the transaction valued at approximately $21 billion in total equity. The acquisition is designed to expand Abbott’s presence in cancer screening diagnostics, including tests used to detect colorectal cancer.

Annual Outlook and Market Context

For the full year, Abbott indicated that it expects adjusted earnings in the range of $5.55 to $5.80 per share.

While the long-term business mix remains diverse, the stock market today focused more on near-term execution risks—especially around nutrition revenue and short-term earnings visibility.

The sharp reaction in the Abbott Laboratories share price highlighted how sensitive healthcare stocks remain to revenue consistency, cost pressures, and guidance clarity.

Summary: Why Abbott Laboratories Share Price Fell Today?

• Abbott shares dropped over 8% in the stock market today
• Q4 revenue came in at $11.5 billion, below expectations
• Nutrition segment underperformed at $1.9 billion
• Q1 earnings guidance landed slightly below market comfort levels
• Medical devices remained stable, while diagnostics stayed subdued

In the short term, sentiment drove the move. Investors processed the numbers, weighed the softer outlook, and hit the sell button. For Abbott, the story now shifts to how the company navigates cost pressures and demand recovery across its core healthcare segments—without the market losing patience again.

Source: Livemint